Aptima HPV test
HPV is responsible for more than 99% of all cervical cancers, which is one of the most common types of cancer affecting women throughout the world.1-3
The Aptima HPV assay identifies high-risk HPV infections by targeting E6/E7 mRNA.4 Studies have show targeting E6/E7 mRNA identifies the presence and activity of a high-risk HPV infection.5,6 Aptima HPV assay utilizes the same excellent sensitivity and improved specificity compared to DNA-based tests allowing clinicians to maximize the benefits of screening while minimizing potential harm.
Maximizing the benefits—excellent sensitivity
The Aptima HPV assay identifies those patients at greatest risk for developing cervical cancer, delivering the same excellent sensitivity to minimize false negative results. In fact, the Aptima HPV assay demonstrates the same excellent sensitivity as DNA-based HPV tests in numerous clinical studies involving over 50,000 women worldwide.4,7-21
Clinical Sensitivity of available HPV test
Minimizes potential harm — improves specificity
Due to false-positives, cervical cancer screening can potentially result in the over-treatment of patients. To help minimize this potential harm, the Aptima HPV assay offers improved specificity, reducing the rate of false positive results. In the NILM (negative for intraepithelial lesion or malignancy) arm of the CLEAR trial, the Aptima HPV assay showed 24% fewer false positive test results compared to DNA-based testing.4 With Aptima HPV, clinicians can more accurately target the right patients for coloposcopy.
Aptima HPV 16 18/45 genotype assay
Recent data suggests that while the incidence of cervical cancer has decreased since the 1970s, the prevalence of adenocarcinoma cases has risen approximately 32% in the same time frame.22
The 2012 consensus guidelines state that “The addition of HPV testing to cytology also enhances the identification of women with adenocarcinoma of the cervix and its precursors”. The Aptima HPV 16 18/45 test was designed with the link to adenocarcinoma in mind. Data suggests that up to 94% of cervical adenocarcinomas are linked to genotypes 16, 18, or 45—in fact, 12% were linked to type 45 alone.23
Not only is HPV type 45 common in cervical adenocarcinomas, data also indicates that it is the third most common HPV genotype all invasive cervical cancers-including squamous cell carcinoma.24-25
Fortunately, HPV genotype 45 is fairly uncommon, identified in only 4% of women with normal cytology. By including HPV type 45 in addition to types 16 and 18, the Aptima HPV 16 18/45 Genotype assay may help identify more women at risk for cervical cancer with a minimal impact to colposcopy rates.24-25
Aptima HPV 16 18/45 genotype assay from Hologic — next generation technology, today.